CN101474346B - 薤白提取物及其制备方法与应用 - Google Patents
薤白提取物及其制备方法与应用 Download PDFInfo
- Publication number
- CN101474346B CN101474346B CN 200910077042 CN200910077042A CN101474346B CN 101474346 B CN101474346 B CN 101474346B CN 200910077042 CN200910077042 CN 200910077042 CN 200910077042 A CN200910077042 A CN 200910077042A CN 101474346 B CN101474346 B CN 101474346B
- Authority
- CN
- China
- Prior art keywords
- extract
- group
- bulbus allii
- allii macrostemonis
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 94
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 241000304531 Allium macrostemon Species 0.000 title claims abstract description 14
- 238000000605 extraction Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 13
- 238000010992 reflux Methods 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 9
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims abstract description 7
- 244000295724 Allium chinense Species 0.000 claims abstract description 6
- 235000016790 Allium chinense Nutrition 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 65
- 239000003814 drug Substances 0.000 claims description 40
- 230000004060 metabolic process Effects 0.000 claims description 32
- 208000011580 syndromic disease Diseases 0.000 claims description 32
- 238000000746 purification Methods 0.000 claims description 8
- 230000000274 adsorptive effect Effects 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 238000010936 aqueous wash Methods 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 238000002242 deionisation method Methods 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 47
- 239000008280 blood Substances 0.000 abstract description 47
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 25
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 11
- 230000037149 energy metabolism Effects 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 9
- 210000002027 skeletal muscle Anatomy 0.000 abstract description 8
- 230000006870 function Effects 0.000 abstract description 5
- 230000001965 increasing effect Effects 0.000 abstract description 5
- 230000037356 lipid metabolism Effects 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 210000000579 abdominal fat Anatomy 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 44
- 230000000694 effects Effects 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 29
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 24
- 102000004877 Insulin Human genes 0.000 description 22
- 108090001061 Insulin Proteins 0.000 description 22
- 229940125396 insulin Drugs 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 20
- 230000037396 body weight Effects 0.000 description 19
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 17
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 17
- 239000008103 glucose Substances 0.000 description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 238000002481 ethanol extraction Methods 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102100033223 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 13
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 description 13
- 102100038246 Retinol-binding protein 4 Human genes 0.000 description 13
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 13
- 229960003105 metformin Drugs 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 102000000344 Sirtuin 1 Human genes 0.000 description 12
- 108010041191 Sirtuin 1 Proteins 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 101000665882 Homo sapiens Retinol-binding protein 4 Proteins 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 238000013238 high-fat diet model Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- 102000007469 Actins Human genes 0.000 description 8
- 108010085238 Actins Proteins 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000019626 lipase activity Nutrition 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- -1 nitrogen-containing compound Chemical class 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000002705 Glucose Intolerance Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 201000009104 prediabetes syndrome Diseases 0.000 description 5
- 150000005856 steroid saponins Chemical class 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 208000004611 Abdominal Obesity Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000004882 Lipase Human genes 0.000 description 4
- 108090001060 Lipase Proteins 0.000 description 4
- 239000004367 Lipase Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010065941 Central obesity Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000032696 parturition Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- 101710137011 Retinol-binding protein 4 Proteins 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000001399 anti-metabolic effect Effects 0.000 description 2
- 230000003035 anti-peroxidant effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000000556 factor analysis Methods 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 108091005981 phosphorylated proteins Proteins 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- DLNAGMLXUYEHQS-UHFFFAOYSA-N 3-O-beta-D-glucopyranosylserjanic acid Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6O)C(C)(C)C5CCC34C)C2C1)C(=O)O DLNAGMLXUYEHQS-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 102100032534 Adenosine kinase Human genes 0.000 description 1
- 108020000543 Adenylate kinase Proteins 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 1
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HMQLHCKDYUUVRG-UHFFFAOYSA-N macrostemonoside A Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CCC4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HMQLHCKDYUUVRG-UHFFFAOYSA-N 0.000 description 1
- JWWCJQFYNBGCAX-UOUUDHCBSA-N macrostemonoside a Chemical compound O([C@@]1(C2CC3CCC4C5C[C@H]6[C@@H]([C@]5(CCC4[C@@]3(C)CC2)C)[C@@H](C2(OC[C@H](C)CC2)O6)C)[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JWWCJQFYNBGCAX-UOUUDHCBSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 229930002600 steroidal saponin Natural products 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910077042 CN101474346B (zh) | 2009-01-16 | 2009-01-16 | 薤白提取物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910077042 CN101474346B (zh) | 2009-01-16 | 2009-01-16 | 薤白提取物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101474346A CN101474346A (zh) | 2009-07-08 |
CN101474346B true CN101474346B (zh) | 2013-01-02 |
Family
ID=40835175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200910077042 Active CN101474346B (zh) | 2009-01-16 | 2009-01-16 | 薤白提取物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101474346B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107232539A (zh) * | 2017-05-13 | 2017-10-10 | 宁远平 | 苦薤见肿消及其制作方法 |
CN107296877A (zh) * | 2017-06-09 | 2017-10-27 | 吉林瑞诺科技有限公司 | 一种薤白分组皂苷的制备方法 |
CN108815352A (zh) * | 2018-08-07 | 2018-11-16 | 江西省农业科学院蔬菜花卉研究所 | 一种薤白皂苷提取物的提取工艺 |
CN109431944B (zh) * | 2018-12-26 | 2021-07-09 | 上海应用技术大学 | 一种薤白提取物及其在抗氧化功效化妆品中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1237432A (zh) * | 1998-05-07 | 1999-12-08 | 沈阳药科大学 | 中药薤白改善高血脂症组成物 |
CN1280851A (zh) * | 1999-07-15 | 2001-01-24 | 沈阳药科大学 | 中药薤白改善高血脂症组成物 |
CN1927329A (zh) * | 2006-09-11 | 2007-03-14 | 天津大学 | 一种治疗心血管疾病的药物及其制备方法 |
CN101244190A (zh) * | 2008-01-31 | 2008-08-20 | 浙江大学 | 一种薤白总甾体皂苷提取物的制备方法及其用途 |
-
2009
- 2009-01-16 CN CN 200910077042 patent/CN101474346B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1237432A (zh) * | 1998-05-07 | 1999-12-08 | 沈阳药科大学 | 中药薤白改善高血脂症组成物 |
CN1280851A (zh) * | 1999-07-15 | 2001-01-24 | 沈阳药科大学 | 中药薤白改善高血脂症组成物 |
CN1927329A (zh) * | 2006-09-11 | 2007-03-14 | 天津大学 | 一种治疗心血管疾病的药物及其制备方法 |
CN101244190A (zh) * | 2008-01-31 | 2008-08-20 | 浙江大学 | 一种薤白总甾体皂苷提取物的制备方法及其用途 |
Non-Patent Citations (2)
Title |
---|
姜勇等.《中药薤白的研究进展》.《天然产物研究与开发》.2000,第12卷(第5期),第74-77页. * |
张卿等.薤白的研究进展.《中国中药杂志》.2003,第28卷(第2期),第105-106页. * |
Also Published As
Publication number | Publication date |
---|---|
CN101474346A (zh) | 2009-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102526478B (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
CN110787233B (zh) | 保肝中药组合物及其提取物和制药用途 | |
CN102526479B (zh) | 一种增强免疫力、降血糖功能的保健药物 | |
CN102526164A (zh) | 防治胰岛素抵抗及其相关代谢综合征的中药组合物 | |
CN101390887A (zh) | 三七总皂苷的药物组合物 | |
CN101474346B (zh) | 薤白提取物及其制备方法与应用 | |
CN108186877A (zh) | 用于气虚血瘀证心肌梗死二级预防的中药组合物 | |
CN102697781B (zh) | 胡芦巴碱作为制备防治糖尿病及其并发症药物的应用 | |
CN103432192B (zh) | 一种具有减肥作用的组合物 | |
CN1558768A (zh) | 一种中药组合物及其制备方法 | |
CN114794478B (zh) | 一种能降低血压血脂血糖的组合物及应用 | |
CN100563682C (zh) | 一种由山楂叶与红景天制成的药物组合物及其制备方法 | |
CN105327115B (zh) | 一种防治ⅱ型糖尿病桑黄通泻配方及制备工艺 | |
CN104605051B (zh) | 双麻杜仲叶茶和制法 | |
CN103977390A (zh) | 一种生姜洋葱药酒组合物的制备方法及其用途 | |
CN100579564C (zh) | 一种治疗痛风的药物及其制备方法 | |
CN103750304B (zh) | 一种泽泻减肥降脂保健口服液及其制备方法 | |
KR20100111088A (ko) | 복합 생약 추출물을 유효성분으로 함유하는 당뇨병 또는 이로 인한 합병증의 예방 및 치료용 조성물 | |
CN105998196A (zh) | 一种含绞股蓝的降血糖保健药物组合物 | |
CN109966283A (zh) | 脱脂肉桂多酚提取物在制备防治糖尿病肾病产品中的应用 | |
CN105533749A (zh) | 一种含淫羊藿、五味子的保健食品及其制备方法和用途 | |
CN101143203A (zh) | 一种具有护肝养胃功能的复方口服液 | |
CN105998098A (zh) | 一种制备治疗糖尿病肾病的中药组合物的方法 | |
CN108743885A (zh) | 一种治疗糖尿病大血管病变的中药及其制备方法 | |
CN103860877A (zh) | 一种治疗糖尿病的药物组合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: Second floor, building a, Tsinghua campus, Shenzhen University Town, Xili street, Nanshan District, Shenzhen City, Guangdong Province Patentee after: Tsinghua Shenzhen International Graduate School Address before: 518055 Guangdong city in Shenzhen Province, Nanshan District City Xili Town, Shenzhen University, Tsinghua Campus Patentee before: GRADUATE SCHOOL AT SHENZHEN, TSINGHUA University |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230810 Address after: G106, Floor 1, Yangji Commercial Plaza, Xinzhou Road East, Xingang Community, Fubao Street, Futian District, Shenzhen, Guangdong 518000 Patentee after: Qiai Life Technology (Shenzhen) Co.,Ltd. Address before: Second floor, building a, Tsinghua campus, Shenzhen University Town, Xili street, Nanshan District, Shenzhen City, Guangdong Province Patentee before: Tsinghua Shenzhen International Graduate School |
|
TR01 | Transfer of patent right |